Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brian Yang

Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.

Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.

Set Alert for Articles By Brian Yang

Latest From Brian Yang

Long Serving Deputy Becomes China Health Commissioner

China's third-ranked health official Ma Xiaowei has been promoted to the top position, leading an agency transforming itself from treating diseases to health policy-making against a backdrop of a fast-aging population, emerging data and new AI technologies.

Appointments Asia Pacific

Asia Executives To Watch: Takeda, Asahi Kasei, Actelion, WuXi NextCode

Takeda appoints a new chief financial official, the third in recent years, and a new consumer health CEO, while WuXi NextCode taps its COO to lead the genomics firm. Senior executives changes also take place at PAREXEL, Asahi Kasei Pharma, and Actelion Japan.

Appointments Asia Pacific

Goodbye CFDA, Hello MRA: China Overhauls Regulatory Bodies

China proposes to merge its top drug and device regulator into a new combined body and create a medical reimbursement agency in moves directed at strengthening regulatory oversight.

Regulation Reimbursement

Goodbye CFDA, Hello MRA: China Overhauls Regulatory Bodies

China proposes to merge its top drug regulator into new combined body, and creates a medical reimbursement agency in move viewed as sign of strengthening regulatory oversight.
Reimbursement Regulation

China Talks Up AI, Big Data, Cancer Care But Approval, Coverage Huddles Persist

Leveraging the internet and big data to improve healthcare, regulatory efficiency and cancer treatment are among the priorities singled out by the Chinese Premier at the annual National People's Congress meeting. Some delegates say drug approval and coverage challenges remain, while industry observers point to commercial insurance as a solution to drive the specialty market such as cancer care.

China Policy

China's Harbour BioMed Mulls Global Licensing

The Shanghai-based biotech startup Harbour Biomed hopes overseas licensing will propel it towards an initial offering in the US, following in the footsteps of a successful approach pioneered by BeiGene.

China Commercial
See All